Novostia SA is a development stage company in the business of designing, manufacturing and marketing a revolutionary prosthetic heart valve known as the Lapeyre-Triflo Valve (“LTV”).
The company has been incorporated on April 2017 in Neuchatel, Switzerland, as the vehicle for the project re-start and owns all the intellectual property rights, patents and assets.
The LTV is a mechanical tri-leaflet heart valve that has the geometry and function similar to the human heart valve. It is designed to eradicate the need of lifelong anticoagulation therapy, behaving physiologically like a tissue valve, and to be resistant to structural failure (“one valve for life”).
The LTV is made of strong high performance biocompatible material (polymer, titanium, polyester). The surgical handling is identical to current surgical heart valves.
Over twenty-five years of research with prominent research laboratories as well as with leaders in fluid mechanics and high precision manufacturers have led to this new concept of prosthetic heart valve.
Novostia is in pre-clinical phase and is working closely with key opinion leaders to prepare the clinical phase for this long waited heart valve solution.
Target Markets: The LTV is designed for all operable patients suffering from a heart valve disease and who need a heart valve replacement, especially young patients.